The summer months are traditionally slow on movements across the industry, but July saw a number of manufacturing partnership deals take place as companies look ahead to product commercialization.
The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.
Thermo Fisher invests into bioproduction capabilities as ‘single use continues to reshape the face of the industry,’ says single-use technology executive.
Patheon NV has announced it will spend $45m to expand and enhance its manufacturing network citing customer demand for more reliable, flexible and cost-efficient supply chains.
A WuXi Biologics facility tipped to be the world’s largest single-use mammalian cell culture site will be equipped with disposable systems from Thermo Fisher.
Thermo Fisher Scientific, Inc. saw revenue grow 8% in 2016, mostly due to acquisitions of new Chromotography and mass spectrometry tech and expanding its Bioproduction.
